Akums Expands Global Footprint with EU GMP Certification in Europe and UK
In a significant move to broaden its global influence, Akums Drugs & Pharmaceuticals Ltd., recognized as the largest Contract Development and Manufacturing Organization (CDMO) in India, has received certification for Good Manufacturing Practices (EU GMP) for two of its manufacturing facilities. This achievement marks a crucial step in establishing a robust presence in Europe's strictly regulated pharmaceutical markets.
With India often hailed as the 'Pharmacy of the World,' Akums stands out, producing medications for over 1.46 billion consumers and representing nearly 10% of India's total pharmaceutical consumption in volume. This certification comes in the wake of expanding regulatory approval, enhancing Akums' capability to cater to the growing demand in the European sector while adhering to global quality standards.
The EU GMP certification encompasses a renewal for their solid oral dosage plant, responsible for tablets, capsules, and sachets, alongside a new certification for their liquid oral dosage facility, which produces solutions, syrups, and suspensions. Such approvals not only bolster Akums' operational capacity but also affirm its commitment to quality, meeting the rigorous requirements established by international health and safety authorities.
Akums' aspirations extend to making a strong imprint in the UK market, recently securing its initial approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for rivaroxaban, a key anticoagulant. This represents Akums' direct entry into the UK's anticoagulant market, a segment valued at about $2.6 billion, highlighting the company's focused ambition to replicate its success on a global scale.
Sandeep Jain, the Managing Director of Akums, expressed enthusiasm about this milestone. He stated, "We have achieved scale, compliance, and credibility in India. Our vision now extends with the same commitment to Europe and the UK. We are determined to replicate what we have accomplished nationally on a global scale, with a foundation in quality, reliability, and long-term partnerships."
Echoing this sentiment, Co-Managing Director Sanjeev Jain elaborated on their operational strengths, noting, "Our manufacturing robustness, regulatory discipline, and development capabilities equip us to enter regulated markets with confidence. This is a calibrated yet ambitious global expansion."
At the heart of Akums' operations is an integrated and innovative research and development ecosystem, which commands a portfolio of over 20,000 stock-keeping units (SKUs). With four advanced R&D centers, expertise in over 60 pharmaceutical forms, and capabilities spanning complex injectables, oral solids, liquids, nutraceuticals, and new drug delivery systems, Akums is well-positioned to deliver competitive pharmaceutical solutions on a global platform.
Currently, Akums services over 1,500 clients worldwide and operates 14 world-class manufacturing plants comprising 12 formulation facilities and 2 Active Pharmaceutical Ingredient (API) plants, collectively boasting a production capacity exceeding 50 billion units annually. This dynamic operational footprint not only evidences Akums' prowess in the pharmaceutical domain but also sets the stage for expansive endeavors in Europe and beyond. As Akums solidifies its status as a pivotal player in the international pharmaceutical landscape, its commitment to enhancing healthcare outcomes through innovation and quality assurance is unmistakable.
With India often hailed as the 'Pharmacy of the World,' Akums stands out, producing medications for over 1.46 billion consumers and representing nearly 10% of India's total pharmaceutical consumption in volume. This certification comes in the wake of expanding regulatory approval, enhancing Akums' capability to cater to the growing demand in the European sector while adhering to global quality standards.
The EU GMP certification encompasses a renewal for their solid oral dosage plant, responsible for tablets, capsules, and sachets, alongside a new certification for their liquid oral dosage facility, which produces solutions, syrups, and suspensions. Such approvals not only bolster Akums' operational capacity but also affirm its commitment to quality, meeting the rigorous requirements established by international health and safety authorities.
Akums' aspirations extend to making a strong imprint in the UK market, recently securing its initial approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for rivaroxaban, a key anticoagulant. This represents Akums' direct entry into the UK's anticoagulant market, a segment valued at about $2.6 billion, highlighting the company's focused ambition to replicate its success on a global scale.
Sandeep Jain, the Managing Director of Akums, expressed enthusiasm about this milestone. He stated, "We have achieved scale, compliance, and credibility in India. Our vision now extends with the same commitment to Europe and the UK. We are determined to replicate what we have accomplished nationally on a global scale, with a foundation in quality, reliability, and long-term partnerships."
Echoing this sentiment, Co-Managing Director Sanjeev Jain elaborated on their operational strengths, noting, "Our manufacturing robustness, regulatory discipline, and development capabilities equip us to enter regulated markets with confidence. This is a calibrated yet ambitious global expansion."
At the heart of Akums' operations is an integrated and innovative research and development ecosystem, which commands a portfolio of over 20,000 stock-keeping units (SKUs). With four advanced R&D centers, expertise in over 60 pharmaceutical forms, and capabilities spanning complex injectables, oral solids, liquids, nutraceuticals, and new drug delivery systems, Akums is well-positioned to deliver competitive pharmaceutical solutions on a global platform.
Currently, Akums services over 1,500 clients worldwide and operates 14 world-class manufacturing plants comprising 12 formulation facilities and 2 Active Pharmaceutical Ingredient (API) plants, collectively boasting a production capacity exceeding 50 billion units annually. This dynamic operational footprint not only evidences Akums' prowess in the pharmaceutical domain but also sets the stage for expansive endeavors in Europe and beyond. As Akums solidifies its status as a pivotal player in the international pharmaceutical landscape, its commitment to enhancing healthcare outcomes through innovation and quality assurance is unmistakable.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.